MicroRNA‑423 promotes proliferation, migration and invasion and induces chemoresistance of endometrial cancer cells

Li,Jie; Sun,Huijie; Liu,Ting; Kong,Jian

doi:10.3892/etm.2018.6710

MicroRNA‑423 promotes proliferation, migration and invasion and induces chemoresistance of endometrial cancer cells

Authors:
- Jie Li
- Huijie Sun
- Ting Liu
- Jian Kong
View Affiliations

Affiliations: Department of Geriatrics, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: September 7, 2018 https://doi.org/10.3892/etm.2018.6710
Pages: 4213-4224

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Altered microRNA expression serves essential roles in tumorigenesis and progression in endometrial cancer. In the present study the effect of miR‑423 on proliferation, chemosensitivity, migration and invasion of endometrial cancer cells was examined. A WST‑1 assay was used to examine the proliferation of HEC‑1B and Ishikawa endometrial cancer cells with either upregulation or downregulation of miR‑423, with or without cisplatin treatment. The migration and invasion of HEC‑1B and Ishikawa endometrial cancer cells were examined via Transwell migration and Matrigel invasion assays. Protein expression levels, including B cell lymphoma‑2 (Bcl‑2), Bcl‑2 associated X protein, E‑ and N‑cadherin, snail, vimentin, phosphatase and tensin homolog (PTEN) and protein kinase B (AKT) were examined by western blotting. A caspase‑Glo3/7 assay was carried out to evaluate the effect of miR‑423 on cisplatin‑induced apoptosis in HEC‑1B and Ishikawa endometrial cancer cells. Overexpression of miR‑423 enhanced the proliferation, and increased migration and invasion in endometrial cancer cells. miR‑423 also decreased the sensitivity of endometrial cancer cells following cisplatin treatment. miR‑423 inhibited cisplatin‑induced apoptosis in endometrial cancer cells by regulation of caspase 3/7 and Bcl‑2 expression. Furthermore, the E‑cadherin expression was significantly decreased, and the expression of N‑cadherin, snail and Vimentin were increased in both HEC‑1B cells and Ishikawa cells following overexpression of miR‑423. Conversely, downregulation of miR‑423 increased the expression of E‑cadherin and decreased the expression of N‑cadherin, snail and Vimentin. Further experiments demonstrated that the expression levels of PTEN and phosphorylated‑AKT in HEC‑1B and Ishikawa endometrial cancer cells was decreased and increased, respectively, following aberrant expression of miR‑423. miR‑423 displayed an important role in tumorigenesis and progression in endometrial cancer cells, and may therefore be used as a potential biomarker to predict chemotherapy response and prognosis in endometrial cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Xu YY, Wu HJ, Ma HD, Xu LP, Huo Y and Yin LR: MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1. FEBS J. 280:3768–3779. 2013. View Article : Google Scholar : PubMed/NCBI
3	Prat J: Pathology of cancers of the female genital tract. Int J Gynaecol Obstet. 131 Suppl 2:S132–S145. 2015. View Article : Google Scholar : PubMed/NCBI
4	Jin J: Vaginal and urinary symptoms of menopause. JAMA. 317:13882017. View Article : Google Scholar : PubMed/NCBI
5	Dinkelspiel HE, Wright JD, Lewin SN and Herzog TJ: Contemporary clinical management of endometrial cancer. Obstet Gynecol Int. 2013:5838912013. View Article : Google Scholar : PubMed/NCBI
6	Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C and Sessa C: ESMO Guidelines Working Group: Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24 Suppl 6:vi33–vi38. 2013. View Article : Google Scholar : PubMed/NCBI
7	Davidson BA, Foote J, Clark LH, Broadwater G, Ehrisman J, Gehrig P, Graybill W, Secord Alvarez A and Havrilesky LJ: Tumor grade and chemotherapy response in endometrioid endometrial cancer. Gynecol Oncol Rep. 17:3–6. 2016. View Article : Google Scholar : PubMed/NCBI
8	West KA, Castillo SS and Dennis PA: Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
9	Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, et al: Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 35 Suppl:S78–S103. 2015. View Article : Google Scholar : PubMed/NCBI
10	Johnston SR: Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: Cotargeting signaling pathways. J Natl Cancer Inst. 107:pii: djv212. 2015. View Article : Google Scholar : PubMed/NCBI
11	Catalanotto C, Cogoni C and Zardo G: MicroRNA in control of gene expression: An overview of nuclear functions. Int J Mol Sci. 17:pii: E1712. 2016. View Article : Google Scholar : PubMed/NCBI
12	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
13	Pillai RS: MicroRNA function: Multiple mechanisms for a tiny RNA? RNA. 11:1753–1761. 2005. View Article : Google Scholar : PubMed/NCBI
14	Hiroki E, Suzuki F, Akahira J, Nagase S, Ito K, Sugawara J, Miki Y, Suzuki T, Sasano H and Yaegashi N: MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J Cancer. 131:E395–E404. 2012. View Article : Google Scholar : PubMed/NCBI
15	Wang Z, Wang W, Huang K, Wang Y, Li J and Yang X: MicroRNA-34a inhibits cells proliferation and invasion by downregulating Notch1 in endometrial cancer. Oncotarget. 8:111258–111270. 2017.PubMed/NCBI
16	Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, Zamboni G and Maciejewski R: Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer. 12:3692012. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Riss TL, Moravec RA, Niles AL, et al: Cell viability assaysSittampalam GS, Coussens NP, Brimacombe K, et al: Assay Guidance Manual. Bethesda (MD): 2004, View Article : Google Scholar
19	Yanokura M, Banno K, Iida M, Irie H, Umene K, Masuda K, Kobayashi Y, Tominaga E and Aoki D: MicroRNAS in endometrial cancer: Recent advances and potential clinical applications. EXCLI J. 14:190–198. 2015.PubMed/NCBI
20	Lin J, Huang S, Wu S, Ding J, Zhao Y, Liang L, Tian Q, Zha R, Zhan R and He X: MicroRNA-423 promotes cell growth and regulates G(1)/S transition by targeting p21Cip1/Waf1 in hepatocellular carcinoma. Carcinogenesis. 32:1641–1647. 2011. View Article : Google Scholar : PubMed/NCBI
21	Zhao H, Gao A, Zhang Z, Tian R, Luo A, Li M, Zhao D, Fu L, Fu L, Dong JT and Zhu Z: Genetic analysis and preliminary function study of miR-423 in breast cancer. Tumour Biol. 36:4763–4771. 2015. View Article : Google Scholar : PubMed/NCBI
22	Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K and Croce CM: Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA. 109:3024–3029. 2012. View Article : Google Scholar : PubMed/NCBI
23	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
24	Moxley KM and McMeekin DS: Endometrial carcinoma: A review of chemotherapy, drug resistance, and the search for new agents. Oncologist. 15:1026–1033. 2010. View Article : Google Scholar : PubMed/NCBI
25	Abdullah LN and Chow EK: Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2:32013. View Article : Google Scholar : PubMed/NCBI
26	Zheng HC: The molecular mechanisms of chemoresistance in cancers. Oncotarget. 8:59950–59964. 2017.PubMed/NCBI
27	Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
28	Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV and Cheng JQ: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68:425–433. 2008. View Article : Google Scholar : PubMed/NCBI
29	Kong W, He L, Coppola M, Esposito NN, Coppola D and Cheng JQ: MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 291:228552016. View Article : Google Scholar : PubMed/NCBI
30	Yu Z, Xu Z, Disante G, Wright J, Wang M, Li Y, Zhao Q, Ren T, Ju X, Gutman E, et al: miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget. 5:1083–1090. 2014. View Article : Google Scholar : PubMed/NCBI
31	Li L and Li W: Epithelial-mesenchymal transition in human cancer: Comprehensive reprogramming of metabolism, epigenetics, and differentiation. Pharmacol Ther. 150:33–46. 2015. View Article : Google Scholar : PubMed/NCBI
32	Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI
33	Xie Y, Naizabekov S, Chen Z and Tokay T: Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes. Oncol Lett. 12:375–378. 2016. View Article : Google Scholar : PubMed/NCBI
34	Xu W, Yang Z, Zhou SF and Lu N: Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors. Drug Des Devel Ther. 8:1745–1751. 2014. View Article : Google Scholar : PubMed/NCBI
35	Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB and Broaddus RR: Clinical assessment of PTEN loss in endometrial carcinoma: Immunohistochemistry outperforms gene sequencing. Mod Pathol. 25:699–708. 2012. View Article : Google Scholar : PubMed/NCBI